Komori
PhoenixBio (6190) · RiskWorsened

Tax Loss Carryforwards and Future Tax Burden

First written in FY2016. 5 of 10 entries say "Worsened", first in FY2017. Latest entry: FY2026.

10entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseWorsenedFY2017 – FY2018MitigatedFY2019 – FY2020MitigatedFY2022 – FY20232016: 120162017: 120172018: 120182019: 120192020: 120202021: 120212022: 120222023: 120232024: 020242025: 120252026: 12026
Same theme, other companies
Increase in corporate tax burden due to the disallowance and reversal of tax loss carryforwardsA theme 125 companies write about · 125 as a headwind · 0 as a tailwind

PhoenixBio moved to the "Worse" side of this theme in 2017, 7 years before the typical company in this theme (2024).

The whole theme swung hardest in 2026: 28 of 56 companies on the "Worse" side.

31 other companies' latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 125 companies compared. The sentences above are computed from all 125.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「As of 31 March 2026, the Group had tax loss carryforwards of ¥1,550.623 million.」

    Tax loss carryforwards increased from ¥1,042.815 million in the previous full-year disclosure to ¥1,550.623 million, and the risk of a higher tax burden after their utilization in the future has increased.
  2. FY2025WorsenedAnnual report

    「As of 31 March 2025, the Group had tax loss carryforwards of ¥1,042.815 million.」

    Tax loss carryforwards increased from ¥703.265 million in the previous full-year disclosure to ¥1,042.815 million, and the risk of a higher tax burden after their utilization in the future has increased.
  3. FY2023MitigatedAnnual report

    「As of 31 March 2023, the Group had tax loss carryforwards of ¥703.265 million.」

    Tax loss carryforwards decreased from ¥912.726 million in the previous full-year disclosure to ¥703.265 million. The risk of a higher tax burden after their utilization in the future remains.
  4. FY2022MitigatedAnnual report

    「As of 31 March 2022, the Group had tax loss carryforwards of ¥912.726 million.」

    Tax loss carryforwards decreased from ¥984.028 million in the previous fiscal year to ¥912.726 million. The risk of a higher tax burden after their utilization remains.
  5. FY2021WorsenedAnnual report

    「As of 31 March 2021, the Group had tax loss carryforwards of ¥984.028 million.」

    Tax loss carryforwards increased from ¥973.706 million in the previous fiscal year to ¥984.028 million, and the risk of a higher tax burden after their utilization in the future remains.
  6. FY2020MitigatedAnnual report

    「As of 31 March 2020, the Group had tax loss carryforwards of ¥973.706 million.」

    Tax loss carryforwards decreased from ¥1,096.890 million in the previous fiscal year to ¥973.706 million. The risk of a higher tax burden after their utilization remains.
  7. FY2019MitigatedAnnual report

    「As of 31 March 2019, the Group had tax loss carryforwards of ¥1,096.890 million.」

    Tax loss carryforwards decreased from ¥1,132.225 million in the previous fiscal year to ¥1,096.890 million. The risk of a higher tax burden after their utilization remains.
  8. FY2018WorsenedAnnual report

    「As of 31 March 2018, our group had tax loss carryforwards of ¥1,132.225 million.」

    Tax loss carryforwards increased from ¥1,100.387 million in the previous fiscal year to ¥1,132.225 million, and the risk of a higher tax burden after they are utilized in the future remains.
  9. FY2017WorsenedAnnual report

    「As of 31 March 2017, our group had tax loss carryforwards of ¥1,100.387 million.」

    Tax loss carryforwards increased from ¥1,071.769 million in the previous fiscal year to ¥1,100.387 million. The risk of a higher tax burden after their utilization continues.
  10. FY2016First statedAnnual report

    「As of 31 March 2016, our company had tax loss carryforwards of ¥1,071.769 million. However, once these tax loss carryforwards are fully utilized, the tax burden is expected to increase, affecting net income.」

    Tax loss carryforwards were quantified at ¥1,071.769 million, and the increase in the tax burden after their utilization was described.
Moved together

"Expansion in the DMPK/Tox field" moved the same way as this thread, in the same document, in 5 of its 10 moves.

554433★123456
  1. ★This thread
  2. 1Expansion in the DMPK/Tox field5×
  3. 2Dependence on the Anti-Hepatitis Virus Drug Market and Market Convergence5×
  4. 3Establishment of a PXB mouse supply system in the United States4×
  5. 4Joint Research and Business Relationships with Hiroshima University4×
  6. 5Application Development for PXB Mice and Establishment of Intellectual Property Rights3×
  7. 6Uncertainty over the outlook due to U.S. administration policy and geopolitical risks3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for PhoenixBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Tax Loss Carryforwards and Future Tax Burden | PhoenixBio Co.,Ltd. (6190) | Komori